Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

Antimetabolites, Antineoplastic / administration & dosage Congresses as Topic / standards Drug Monitoring / methods Fluorouracil / administration & dosage Humans Internationality Medical Oncology / methods Netherlands

Journal

Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741

Informations de publication

Date de publication:
03 2019
Historique:
received: 05 03 2018
accepted: 09 05 2018
pubmed: 21 6 2018
medline: 20 12 2019
entrez: 21 6 2018
Statut: ppublish

Résumé

5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

Identifiants

DOI: 10.1002/cpt.1124 PMID: 29923599 PMC: PMC6309286
pubmed: 29923599
doi: 10.1002/cpt.1124
pmc: PMC6309286
mid: NIHMS972210
doi:

Substances chimiques

Antimetabolites, Antineoplastic 0
Fluorouracil U3P01618RT

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

598-613

Subventions

Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186690
Pays : United States

Informations de copyright

© 2018 American Society for Clinical Pharmacology and Therapeutics.

Références

Clin Colorectal Cancer. 2014 Dec;13(4):219-25
pubmed: 25306485
Cancer Res. 1990 Jan 1;50(1):197-201
pubmed: 2293556
Cancer Res. 1982 Jul;42(7):2930-7
pubmed: 6211226
Cancer Res. 2013 Mar 15;73(6):1958-68
pubmed: 23328581
Cancer Chemother Pharmacol. 2016 Dec;78(6):1253-1261
pubmed: 27807652
Br J Cancer. 1978 Dec;38(6):719-24
pubmed: 743489
J Clin Oncol. 1994 Jun;12(6):1291-5
pubmed: 8201391
Clin Cancer Res. 2008 May 1;14(9):2749-55
pubmed: 18451241
Anal Bioanal Chem. 2010 Jun;397(3):1191-201
pubmed: 20383700
Clin Colorectal Cancer. 2007 Mar;6(6):407-22
pubmed: 17539192
Clin Colorectal Cancer. 2011 Sep;10(3):203-6
pubmed: 21855044
Clin Pharmacol Ther. 2006 Oct;80(4):384-95
pubmed: 17015056
Clin Pharmacokinet. 2012 Mar 1;51(3):163-74
pubmed: 22339448
Oncologist. 2007 Aug;12(8):913-23
pubmed: 17766650
Clin Cancer Res. 2016 Sep 15;22(18):4545-9
pubmed: 27401247
Ther Drug Monit. 2016 Feb;38(1):79-86
pubmed: 26309030
Pharmacogenomics J. 2013 Oct;13(5):389-95
pubmed: 23856855
Ann Oncol. 2011 Jul;22(7):1535-46
pubmed: 21228335
Pharmacogenomics. 2015;16(11):1277-86
pubmed: 26265346
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Clin Pharmacol Ther. 2013 Mar;93(3):228-30
pubmed: 23419487
J Clin Oncol. 1991 Nov;9(11):2027-35
pubmed: 1941062
J Clin Oncol. 1996 May;14(5):1663-71
pubmed: 8622086
BMC Cancer. 2015 Feb 18;15:69
pubmed: 25885822
J Clin Oncol. 2015 Mar 1;33(7):692-700
pubmed: 25605843
J Clin Oncol. 2016 Jan 20;34(3):227-34
pubmed: 26573078
Cancer Chemother Pharmacol. 1990;26(5):352-4
pubmed: 2208577
Ann Oncol. 2001 Sep;12(9):1301-6
pubmed: 11697844
Cancer. 1993 Dec 15;72(12):3715-22
pubmed: 8252488
Bull Cancer. 1993 May;80(5):439-45
pubmed: 8173197
Biomed Chromatogr. 2013 Jan;27(1):7-16
pubmed: 22454320
Clin Pharmacol Ther. 2002 Dec;72(6):627-37
pubmed: 12496744
Pharmacotherapy. 1997 Sep-Oct;17(5):881-6
pubmed: 9324177
Rapid Commun Mass Spectrom. 2008;22(2):224-30
pubmed: 18085512
Clin Cancer Res. 1998 Sep;4(9):2039-45
pubmed: 9748117
Cancer Chemother Pharmacol. 2013 Feb;71(2):361-70
pubmed: 23139054
Clin Pharmacol Ther. 2000 Sep;68(3):270-9
pubmed: 11014408
Cancer Res. 1993 Nov 15;53(22):5433-8
pubmed: 8221682
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
J Clin Oncol. 1999 Apr;17(4):1105
pubmed: 10561167
Br J Cancer. 1989 Feb;59(2):287-90
pubmed: 2930694
Oncologist. 2012;17(3):296-302
pubmed: 22382460
J Breath Res. 2009 Dec;3(4):047002
pubmed: 21386199
Cancer Chemother Pharmacol. 2003 Oct;52(4):282-90
pubmed: 12827293
Pharmacopsychiatry. 2011 Sep;44(6):195-235
pubmed: 21969060
J Clin Oncol. 1994 Nov;12(11):2248-53
pubmed: 7964939
Clin Cancer Res. 2004 Apr 15;10(8):2652-8
pubmed: 15102667
Health Technol Assess. 2015 Nov;19(91):1-321, v-vi
pubmed: 26542268
Am J Health Syst Pharm. 2013 Jul 1;70(13):1100
pubmed: 23784153
Lancet. 2000 May 6;355(9215):1588-96
pubmed: 10821362
Int J Med Sci. 2010 Jan 31;7(1):48-54
pubmed: 20151048
Br J Pharmacol. 2004 Feb;141(4):616-23
pubmed: 14744810
Cancer Biol Ther. 2011 Oct 1;12(7):557-68
pubmed: 21931273
Biomed Chromatogr. 2002 Oct;16(7):446-52
pubmed: 12378555
Br J Clin Pharmacol. 2016 Mar;81(3):553-61
pubmed: 26551538
Cancer. 1996 Feb 1;77(3):441-51
pubmed: 8630950
Clin Pharmacokinet. 2005;44(2):147-73
pubmed: 15656695
Cancer Res. 1992 May 15;52(10):2899-902
pubmed: 1581906
N Engl J Med. 2004 Jun 3;350(23):2343-51
pubmed: 15175436
J Clin Oncol. 2002 Mar 15;20(6):1683-91
pubmed: 11896120
Clin Cancer Res. 2006 Jan 15;12(2):549-55
pubmed: 16428499
Ann Oncol. 2006 Nov;17(11):1656-60
pubmed: 16968871
Clin Pharmacokinet. 2006;45(6):567-92
pubmed: 16719540
Clin Colorectal Cancer. 2012 Dec;11(4):263-7
pubmed: 22683364
Oncologist. 2014 Sep;19(9):959-65
pubmed: 25117066
Cancer Res. 1988 Dec 1;48(23):6956-61
pubmed: 3180104
Cancer Chemother Pharmacol. 2016 Sep;78(3):447-64
pubmed: 27217046
Ther Drug Monit. 2002 Oct;24(5):588-93
pubmed: 12352929
Ther Drug Monit. 2009 Dec;31(6):688-94
pubmed: 19935361
Cancer Treat Rev. 2017 May;56:1-7
pubmed: 28437678
J Natl Cancer Inst. 1993 Jun 16;85(12):1005-7
pubmed: 8496975
Cancer Chemother Pharmacol. 1986;16(1):64-6
pubmed: 3940221
Clin Chem. 1987 Dec;33(12):2299-300
pubmed: 3484334
Cancer Chemother Pharmacol. 2013 Dec;72(6):1273-82
pubmed: 24101147
N Engl J Med. 1998 Feb 19;338(8):499-505
pubmed: 9468466
Cancer. 2017 Jan 1;123(2):345-356
pubmed: 27622829
Clin Pharmacol Ther. 2016 Feb;99(2):235-42
pubmed: 26265035
Acta Oncol. 1996;35(2):207-12
pubmed: 8639317
Clin Colorectal Cancer. 2016 Dec;15(4):381-388
pubmed: 27256667
J Clin Oncol. 1998 Apr;16(4):1470-8
pubmed: 9552054
J Clin Oncol. 2008 May 1;26(13):2099-105
pubmed: 18445839
Clin Colorectal Cancer. 2014 Jun;13(2):119-26
pubmed: 24461492
Chronobiol Int. 2002 Jan;19(1):177-89
pubmed: 11962674
Pharmacogenomics J. 2008 Aug;8(4):256-67
pubmed: 17700593
Clin Pharmacol Ther. 2018 Feb;103(2):210-216
pubmed: 29152729
Int J Cancer. 1988 Apr 15;41(4):537-41
pubmed: 3356488
Ther Drug Monit. 1996 Aug;18(4):335-40
pubmed: 8857547
J Clin Oncol. 1992 Jul;10(7):1171-5
pubmed: 1607921
Br J Cancer. 2001 Mar 2;84(5):600-3
pubmed: 11237378
Clin Pharmacokinet. 2016 Oct;55(10):1205-1216
pubmed: 27138786
Clin Cancer Res. 2000 Aug;6(8):3032-7
pubmed: 10955781
Pharmacogenomics. 2014 Sep;15(13):1653-66
pubmed: 25410891

Auteurs

Jan H Beumer (JH)

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Edward Chu (E)

Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Carmen Allegra (C)

University of Florida, Gainesville, Florida, USA.

Yusuke Tanigawara (Y)

Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan.

Gerard Milano (G)

Oncopharmacology Unit, Centre Antoine Lacassagne, Nice, France.

Robert Diasio (R)

Developmental Therapeutics Program, Mayo Clinic Cancer Center, Rochester, Minnesota, USA.
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic School of Medicine, Rochester, Minnesota, USA.

Tae Won Kim (TW)

Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

Ron H Mathijssen (RH)

Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.

Li Zhang (L)

Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Dirk Arnold (D)

Department of Oncology, AK Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany.

Katsuki Muneoka (K)

Division of Oncology Center, Niitsu Medical Center Hospital, Niigata City, Japan.

Narikazu Boku (N)

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan.

Markus Joerger (M)

Department of Medical Oncology & Hematology, Cantonal Hospital, St. Gallen, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions toxiques › Noxas › Antimétabolites › Antimétabolites antinéoplasiques › Therapeutic Drug Monitoring in Oncology:...
questionsmedicales.fr › Organisations et économie des soins de santé › Organismes › Congrès comme sujet › Therapeutic Drug Monitoring in Oncology:...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Monitorage physiologique › Surveillance des médicaments › Therapeutic Drug Monitoring in Oncology:...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Pyrimidinones › Uracile › Fluorouracil › Therapeutic Drug Monitoring in Oncology:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Therapeutic Drug Monitoring in Oncology:...
questionsmedicales.fr › Sciences sociales › Internationalité › Therapeutic Drug Monitoring in Oncology:...
questionsmedicales.fr › Professions de santé › Médecine › Médecine interne › Oncologie médicale › Therapeutic Drug Monitoring in Oncology:...
questionsmedicales.fr › Régions géographiques › Europe › Pays-Bas › Therapeutic Drug Monitoring in Oncology:...